Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Companyâ€™s research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Companyâ€™s NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	20.49L 17.97L 16.56L 15.5L 29.07L 19Cr 29.68L 1.99Cr 77.02L 9.55Cr 76.95L 75.27L 33Cr	P/E 2003 *	-	P/E 2004	-
Enterprise Value	20.49L 17.97L 16.56L 15.5L 29.07L 19Cr 29.68L 1.99Cr 77.02L 9.55Cr 76.95L 75.27L 33Cr	EV / Sales 2003	-	EV / Sales 2004	-
Free-Float	100%	Yield 2003 *	-	Yield 2004	-

02/24/02	Krystal Biotech, Inc. : Will it go even higher?
31/21/31	NanoSmart Pharmaceuticals, Inc. announced that it has received funding from Oncology Pharma Inc.	CI
10/21/10	Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy	CI
04/21/04	Oncology Pharma Inc. Moves to Fund Lead Drug Formulation & IND-Enabling Studies	CI
26/21/26	Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent	CI
22/21/22	Oncology Pharma Extends Licensing Agreement with Nanosmart Pharmaceuticals, Inc. for Veterinary Oncology	CI
16/21/16	Oncology Pharma Inc. Announces Henry Smith as New Chairman to Its Scientific Advisory Board	CI
09/21/09	Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for Its Connect2med Clinical Trials Platform	CI
29/21/29	Oncology Pharma Announces the Appointment of James Smith as New Chief Financial Officer	CI
11/20/11	Oncology Pharma Inc. cancelled the acquisition of acquire 50% stake in Diagnomics, Inc.	CI
06/20/06	Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating Covid-19	CI
20/19/20	Oncology Pharma Inc. announced that it expects to receive $38.4 million in funding from SCP Partners	CI
11/19/11	Oncology Pharma Inc. signed a Letter of Intent to acquire 50% stake in Diagnomics, Inc.	CI

12/22/12	Oncology Pharma : Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	PU
29/22/29	Oncology Pharma : Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	PU
06/22/06	Oncology Pharma : Financial Statements (Unaudited) for the year ended March 31, 2022	PU
15/22/15	Oncology Pharma : Financial Statements for the period ended December 31, 2021	PU
15/22/15	Oncology Pharma : Disclosure Statement for the period ended December 31, 2021	PU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SOURCINGLINK.NET, INC.	-.--%	+9.50%	-	-	20.49L
ELI LILLY AND COMPANY	+7.13%	+9.97%	+55.80%	+163.38%	1,07700Cr
JOHNSON & JOHNSON	+3.99%	+11.50%	+67.09%	+56.27%	61TCr
ABBVIE INC.	+4.20%	+17.03%	+38.97%	+91.19%	45TCr
ROCHE HOLDING AG	+0.99%	+4.85%	+28.17%	+22.04%	33TCr
ASTRAZENECA PLC	+1.82%	+8.19%	+40.04%	+27.45%	29TCr
NOVARTIS AG	+0.22%	+6.75%	+31.30%	+42.64%	29TCr
NOVO NORDISK A/S	+0.73%	+8.53%	-27.33%	-40.29%	21TCr
AMGEN INC.	+1.56%	+6.14%	+29.30%	+61.91%	19TCr
GILEAD SCIENCES, INC.	+3.26%	+3.33%	+15.55%	+67.87%	16TCr
Average	+2.39%	+8.48%	+30.99%	+54.72%	40.18TCr
Weighted average by Cap.	+3.85%	+9.65%	+41.75%	+81.02%

	2003	2004
Net sales	32.8L 28.76L 26.51L 24.82L 46.54L 31Cr 47.5L 3.19Cr 1.23Cr 15Cr 1.23Cr 1.2Cr 53Cr	11.81L 10.36L 10L 9L 16.76L 11Cr 17.1L 1.15Cr 44.39L 5.51Cr 44.35L 43.38L 19Cr
Net income	-15.2L -13.33L -12.28L -11.5L -21.57L -14Cr -22.01L -1.48Cr -57.13L -7.09Cr -57.08L -55.83L -25Cr	-15.65L -13.72L -12.65L -11.84L -22.2L -15Cr -22.67L -1.52Cr -58.83L -7.3Cr -58.77L -57.48L -25Cr
Net Debt	-13.46L -11.8L -10.88L -10.18L -19.1L -13Cr -19.49L -1.31Cr -50.59L -6.28Cr -50.54L -49.44L -22Cr	17T 14.91T 13.74T 12.86T 24.12T 16.04L 24.62T 2L 63.9T 8L 63.84T 62.44T 27.48L

SourcingLink.net, Inc. Share Price OTC Bulletin Board

Stocks

US8361714053

Pharmaceuticals

Valuation: SourcingLink.net, Inc.

Latest news : SourcingLink.net, Inc.

Press Releases: SourcingLink.net, Inc.

News in other languages: SourcingLink.net, Inc.

Managers and Directors: SourcingLink.net, Inc.

Other Pharmaceuticals

Financials

Company Profile